Sort
10,766 grants matching “checkpoint inhibitor”
Study of the IL-33-driven immune cell organization underpinning responses to immune checkpoint blockade cancer therapy
$132,998Binfeng Lu · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · CA
Durvalumab in Combination with Olaparib in Non-Small Cell Lung Cancer
$132,637Arun Rajan · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Investigating the PD-L1:NLRP3 signaling axis as a tumor intrinsic mechanism of adaptive resistance to anti-PD-1 antibody immunotherapy
$132,629Brent Allen Hanks · Duke University · R37 · FY2022 · CA
Investigating the PD-L1:NLRP3 signaling axis as a tumor intrinsic mechanism of adaptive resistance to anti-PD-1 antibody immunotherapy
$132,629Brent Allen Hanks · Duke University · R37 · FY2021 · CA
Regulation of BRCA1 Function by Protein Phosphatase 1
$132,101Lih-Ching Hsu · National Taiwan University · R01 · FY2009 · CA
Small extracellular vesicles as biomarkers of prognosis and response to therapy in head and neck cancer
$130,976Theresa L. Whiteside · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · DE
Pyk2 inhibition mitigates immunosuppressive environment and enhances therapeutic response to immune checkpoint inhibitors in GBM
$130,869Lilia Kucheryavykh · Universidad Central Del Caribe · R16 · FY2024 · GM
Pyk2 inhibition mitigates immunosuppressive environment and enhances therapeutic response to immune checkpoint inhibitors in GBM
$130,869Lilia Kucheryavykh · Universidad Central Del Caribe · R16 · FY2025 · GM
Analysis of Loss of Function of MAD2 in Mammals
$130,815Sloan-Kettering Institute For Cancer Res · K08 · FY2004 · CA
Analysis of Loss of Function of MAD2 in Mammals
$130,815Sloan-Kettering Institute For Cancer Res · K08 · FY2003 · CA
Analysis of Loss of Function of MAD2 in Mammals
$130,815Sloan-Kettering Institute For Cancer Res · K08 · FY2001 · CA
NEUROPATHOLOGY/TISSUE BANK CORE
$130,357Claudia Katharina Petritsch · Stanford University · U54 · FY2025 · CA
Engineering viral nanoparticles for TLR agonist-based multi-functional cancer immunotherapies
$130,350Zhongchao Zhao · University Of California, San Diego · K99 · FY2025 · CA
Engineering viral nanoparticles for TLR agonist-based multi-functional cancer immunotherapies
$130,350Zhongchao Zhao · University Of California, San Diego · K99 · FY2024 · CA
Personalized targeting of anti-apoptosis pathways to overcome therapeutic resistance in melanoma
$130,262Michael Davies · Wistar Institute · U54 · FY2023 · CA
Understanding and exploiting novel therapeutic vulnerabilities of RIT1-driven lung cancer
$129,789Alice Berger · Fred Hutchinson Cancer Center · R37 · FY2024 · CA
Durvalumab in Combination with Olaparib in Non-Small Cell Lung Cancer
$129,604Arun Rajan · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
αvβ3-induced epithelial cancer progression via macrophage recruitment
$129,411Hiromi Inoue Wettersten · University Of California, San Diego · K01 · FY2023 · OD
αvβ3-induced epithelial cancer progression via macrophage recruitment
$129,411Hiromi Inoue Wettersten · University Of California, San Diego · K01 · FY2024 · OD
αvβ3-induced epithelial cancer progression via macrophage recruitment
$129,411Hiromi Inoue Wettersten · University Of California, San Diego · K01 · FY2025 · OD
αvβ3-induced epithelial cancer progression via macrophage recruitment
$129,411Hiromi Inoue Wettersten · University Of California, San Diego · K01 · FY2022 · OD
αvβ3-induced epithelial cancer progression via macrophage recruitment
$129,411Hiromi Inoue Wettersten · University Of California, San Diego · K01 · FY2021 · OD
Core D: Translational Imaging Core
$129,289Ivan Pedrosa · Ut Southwestern Medical Center · P50 · FY2022 · CA
Lysosome-targeting chimeras degrading immune checkpoint proteins to enhance immunoradiotherapy of head and neck cancer
$129,289Yuyan Jiang · Stanford University · K99 · FY2025 · DE
Improving Pediatric Melanoma Outcomes in a Longitudinally Evaluated Cohort
$129,229Marielle Yohe · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA